Budget Amount *help |
¥17,810,000 (Direct Cost: ¥13,700,000、Indirect Cost: ¥4,110,000)
Fiscal Year 2014: ¥6,630,000 (Direct Cost: ¥5,100,000、Indirect Cost: ¥1,530,000)
Fiscal Year 2013: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2012: ¥6,370,000 (Direct Cost: ¥4,900,000、Indirect Cost: ¥1,470,000)
|
Outline of Final Research Achievements |
FSP1-positive podocytes were observed in active glomerular damage. In this study, we investigated whether secreted FSP1 from podocytes has some biological effects on mesangial cells in vitro and in vivo. We generated recombinant FSP1 (rFSP1) by the standard method. rFSP1 inhibited LPS-induced TNF-α, IL-6, and MCP-1 production and mRNA expression in cultured mesangial cells. LPS injection induced glomerular TNF-αmRNA expression in vivo and this induction was significantly inhibited by the peritoneal injection of rFSP1. Next, we generated transgenic mice (FSP1.TG) in which podocyte-specific overexpressions of FSP1 were observed. LPS-induced glomerular TNF-α expression in FSP1.TG mice was significantly suppressed as compared with control wild mice. These results suggest that secreted FSP1 has renoprotective effects and plays a role in podocyte-mesangial crosstalk.
|